Latest Period
Q2 2026
Security Snapshot
Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (TSHA) Institutional Ownership
CUSIP: 877619106
13F Institutional Holders and Ownership History from Q3 2020 to Q2 2026
Institutions Reporting
207
Shares (Excl. Options)
298,854,516
Price
$6.81
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.00001 par value per share
- Symbol
- TSHA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 298,854,516
- Total 13F value
- $2,034,040,714
- Portfolio coverage rank
- 0%
- Share change
- +33,405,305
- Value change
- +$237,113,975
- Number of holders
- 207
- Shares outstanding
- 332,184,263
- SEC-reported price per share
- $5.96
- Insider filing price
- $5.96
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share is tracked under CUSIP 877619106.
- 207 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 187 to 207 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,182,044,534 to $2,034,040,714.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 207 institutions filings for Q2 2026.
Security key
877619106
Latest holder period
Q2 2026
13F holders
207
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
TSHA full holder history
Taysha Gene Therapies, Inc. SEC filings
Taysha Gene Therapies, Inc. company facts
Taysha Gene Therapies, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 877619106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
TSHA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $176,927,982 | +$28,103,834 | 32,886,242 | +19% | RA Capital Management, L.P. | 30 Jun 2026 |
| Manning Paul B | 9.8% | $59,394,578 | 25,601,111 | Paul B Manning | 30 May 2025 | |||
| RTW INVESTMENTS, LP | 7% | -16% | $92,480,205 | -$12,149,679 | 20,689,084 | -12% | RTW Investments, LP | 31 Mar 2026 |
| Vestal Point Capital, LP | 6.3% | +26% | $80,460,000 | +$18,997,500 | 18,000,000 | +31% | Vestal Point Capital, LP | 31 Mar 2026 |
| BlackRock, Inc. | 6.5% | +26% | $98,187,600 | +$25,844,308 | 17,852,291 | +36% | BlackRock, Inc. | 31 Dec 2025 |
| MORGAN STANLEY | 5.1% | -23% | $87,394,544 | -$3,304,961 | 16,244,339 | -3.6% | Morgan Stanley | 30 Jun 2026 |
| FMR LLC | 4.9% | -22% | $74,406,012 | -$11,547,008 | 13,528,366 | -13% | FMR LLC | 31 Dec 2025 |
| GOLDMAN SACHS GROUP INC | 5.1% | $33,274,806 | 12,748,968 | THE GOLDMAN SACHS GROUP, INC. | 26 Jun 2025 | |||
| Octagon Capital Advisors LP | 3.3% | -36% | $29,650,725 | -$4,520,775 | 9,067,500 | -13% | Octagon Capital Advisors LP | 30 Sep 2025 |
As of 30 Jun 2026, 207 institutional investors reported holding 298,854,516 shares of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (TSHA). This represents 90% of the company’s total 332,184,263 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
74%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 7.2% | 23,888,888 | +10% | 1.5% | $162,683,327 |
| RA CAPITAL MANAGEMENT, L.P. | 7.1% | 23,555,648 | 0% | 1.4% | $160,413,963 |
| GOLDMAN SACHS GROUP INC | 6.8% | 22,713,118 | +1.5% | 0.02% | $154,676,334 |
| BlackRock, Inc. | 6.2% | 20,691,927 | +13% | 0% | $140,912,023 |
| Vestal Point Capital, LP | 5.8% | 19,415,000 | +7.9% | 3.1% | $132,216,150 |
| MORGAN STANLEY | 5% | 16,487,479 | -8.2% | 0.01% | $112,279,731 |
| RTW INVESTMENTS, LP | 4.1% | 13,560,258 | -0.88% | 0.79% | $92,345,357 |
| FMR LLC | 4% | 13,336,413 | -6.9% | 0% | $90,820,969 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 12,478,595 | +22% | 0% | $84,979,232 |
| STATE STREET CORP | 3.4% | 11,421,920 | +1.9% | 0% | $77,783,275 |
| Siren, L.L.C. | 3% | 9,846,579 | +12% | 1.4% | $67,055,203 |
| Octagon Capital Advisors LP | 2.9% | 9,693,244 | +9.4% | 6.1% | $66,010,992 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 6,560,394 | +19% | 0% | $44,685,322 |
| Polar Capital Holdings Plc | 1.5% | 5,117,133 | -9.5% | 0.1% | $34,847,676 |
| MPM BIOIMPACT LLC | 1.4% | 4,500,000 | 1.9% | $30,645,000 | |
| D. E. Shaw & Co., Inc. | 1.3% | 4,398,652 | -0.65% | 0.02% | $29,954,821 |
| BAKER BROS. ADVISORS LP | 1.2% | 4,004,756 | 0% | 0.14% | $27,272,388 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.2% | 3,975,605 | +535% | 0% | $27,073,870 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1.2% | 3,885,501 | +35% | 0.04% | $26,460,262 |
| Casdin Capital, LLC | 0.98% | 3,250,000 | 0% | 1.1% | $22,132,500 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.95% | 3,140,009 | +55% | 0% | $21,383,461 |
| ADAR1 Capital Management, LLC | 0.92% | 3,040,466 | +2% | 0.98% | $20,705,573 |
| Pictet Asset Management Holding SA | 0.83% | 2,770,701 | +14243% | 0.02% | $18,868,474 |
| Aberdeen Group plc | 0.7% | 2,327,152 | +128% | 0.02% | $15,847,905 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 0.68% | 2,250,000 | 0.09% | $15,322,500 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Latest
Q2 2026
Rows shown
1-24 of 24
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 298,854,516 | $2,034,040,714 | +$237,113,975 | $6.81 | 207 |
| 2026 Q1 | 264,720,110 | $1,182,044,534 | -$21,469,003 | $4.47 | 187 |
| 2025 Q4 | 269,009,134 | $1,479,387,583 | +$50,473,906 | $5.50 | 195 |
| 2025 Q3 | 264,455,712 | $864,768,038 | +$29,349,082 | $3.27 | 152 |
| 2025 Q2 | 257,684,976 | $595,324,582 | +$211,768,578 | $2.31 | 147 |
| 2025 Q1 | 166,761,354 | $231,855,383 | -$5,171,826 | $1.39 | 124 |
| 2024 Q4 | 167,381,791 | $289,604,775 | +$18,983,312 | $1.73 | 126 |
| 2024 Q3 | 156,893,147 | $315,365,141 | -$17,620,277 | $2.01 | 114 |
| 2024 Q2 | 158,086,076 | $354,139,573 | +$33,881,138 | $2.24 | 102 |
| 2024 Q1 | 140,148,555 | $402,080,424 | +$33,453,660 | $2.87 | 106 |
| 2023 Q4 | 130,129,882 | $230,288,972 | -$12,329,934 | $1.77 | 85 |
| 2023 Q3 | 129,862,060 | $410,364,849 | +$376,246,041 | $3.16 | 59 |
| 2023 Q2 | 13,698,356 | $9,051,371 | -$2,014,707 | $0.66 | 37 |
| 2023 Q1 | 16,687,605 | $13,286,354 | -$3,025,814 | $0.80 | 42 |
| 2022 Q4 | 19,375,255 | $43,785,515 | +$12,385,904 | $2.26 | 51 |
| 2022 Q3 | 13,927,007 | $27,020,000 | -$1,811,564 | $1.93 | 48 |
| 2022 Q2 | 14,700,530 | $54,695,000 | -$11,594,670 | $3.72 | 55 |
| 2022 Q1 | 17,015,055 | $110,894,239 | -$16,224,000 | $6.52 | 70 |
| 2021 Q4 | 18,503,286 | $215,562,592 | -$15,412,583 | $11.65 | 64 |
| 2021 Q3 | 19,436,846 | $361,910,267 | +$4,396,852 | $18.62 | 48 |
| 2021 Q2 | 18,320,557 | $388,394,891 | +$15,022,269 | $21.20 | 48 |
| 2021 Q1 | 17,661,042 | $358,518,075 | -$11,587,017 | $20.30 | 46 |
| 2020 Q4 | 17,998,551 | $475,216,635 | +$32,037,839 | $26.54 | 51 |
| 2020 Q3 | 16,580,732 | $366,712,000 | +$366,712,000 | $22.40 | 46 |